Advertisement

Organisation › Details
Earlybird (Group)
Earlybird Venture Capital focuses on European technology companies. Founded in 1997, Earlybird identifies and backs exceptional early-stage companies on a pan-European basis and supports them through their growth and development phases – providing financial resources, strategic support, plus access to an international network and capital markets. Earlybird invests out of a family of independently-managed funds. Flagship funds with early-stage focus include Digital West (Western Europe), Digital East (Emerging Europe), and Health. Newer funds Earlybird-X (pre-seed in Western Europe & university spinoffs) and Growth Opportunities (a pan-Earlybird growth fund) offer even more agility. With EUR 2 billion under management across all fund streams, 9 IPOs, and 31 trade sales, Earlybird is one of Europe’s most established and active venture capital firms. *
![]() |
Start | 1997-01-01 established |
![]() |
Industry | venture capital |
![]() |
Person | Brandis, Hendrik (Earlybird 201807 Managing Director) |
Person 2 | Nagel, Christian (Earlybird 201807 Managing Director) | |
![]() |
Region | München (Munich) |
Country | Germany | |
Street | 14 Maximilianstr. | |
City | 80539 München | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
Currency | EUR | |
Annual sales | 2,000,000,000 (capital under management (2022) 2022-06-13) | |
* Document for »About Section«: | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Earlybird (Group)
- [1] Prothea Technologies Ltd.. (4/9/24). "Press Release: Prothea Technologies Launches with €12M Series A to Innovate Lung Cancer Diagnosis and Treatment". Edinburgh....
- [2] Earlybird VC Management GmbH & Co KG. (2/14/24). "Press Release: Earlybird Health Closes Fresh Fund of EUR 173m". Berlin & Cologne....
- [3] ImCheck Therapeutics SAS. (6/13/22). "Press Release: ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunothe...
- [4] Noscendo GmbH. (4/23/20). "Press Release: Noscendo Closes Series A Financing and Launches DISQVER in Europe to Significantly Improve Diagnosis of Infectious Diseases". Duisburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top